RBC
AVIR icon

Romano Brothers & Co’s Atea Pharmaceuticals AVIR Stock Holding History

Romano Brothers & Co’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-48
Closed -$231 – 346
2022
Q4 		$231 Buy
+48
New +$243 ﹤0.01% 1040

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Romano Brothers & Co's AVIR Position: Q1 2023 in Review

Romano Brothers & Co sold out of Atea Pharmaceuticals (AVIR) in Q1 2023, closing a stake of 48 shares — an estimated $231 sold.

Romano Brothers & Co first reported a position in AVIR in Q4 2022 and held it in 1 quarter. The position peaked at $231 in Q4 2022. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

  • Romano Brothers & Co reported no remaining Atea Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Romano Brothers & Co sold 48 Atea Pharmaceuticals shares in Q1 2023, an estimated $231.
  • Romano Brothers & Co first reported a position in Atea Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Romano Brothers & Co's Atea Pharmaceuticals position peaked at $231 in Q4 2022.
  • 130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.